SMTL ID : 4cni.1 (1 other biounit)

Crystal structure of the Fab portion of Olokizumab in complex with IL- 6

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.20 Å

Oligo State

hetero-1-1-1-mer

Ligands

1 x TAM: TRIS(HYDROXYETHYL)AMINOMETHANE(Non-covalent)

TAM.1: 7 residues within 4Å: Chain A: Y.32, R.100, E.101, S.102, Y.103, F.106, S.108 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:F.106 Hydrogen bonds: A:R.100, A:R.100, A:Y.103, A:S.108 Water bridges: A:Y.32, A:Y.32

2 x SO4: SULFATE ION(Non-functional Binders)

SO4.2: 3 residues within 4Å: Chain C: R.27, H.151, K.158 4 PLIP interactions: 4 interactions with chain C Water bridges: C:K.158 Salt bridges: C:R.27, C:H.151, C:K.158 SO4.3: 3 residues within 4Å: Chain C: Q.4, P.5, L.6 3 PLIP interactions: 3 interactions with chain C Hydrogen bonds: C:Q.4, C:L.6 Water bridges: C:R.11

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Shaw, S. et al., Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing Gp130-Signaling. Mabs (2014)

Release Date

2014-04-30

Peptides

OLOKIZUMAB HEAVY CHAIN, FAB PORTION: A
OLOKIZUMAB LIGHT CHAIN, FAB PORTION: B
INTERLEUKIN-6: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
D

OLOKIZUMAB HEAVY CHAIN, FAB PORTION

OLOKIZUMAB LIGHT CHAIN, FAB PORTION

INTERLEUKIN-6

Related Entries With Identical Sequence